TMCI TREACE MEDICAL CONCEPTS, INC.companySEC Filings & Insider Trading Activity 2026
Latest TREACE MEDICAL CONCEPTS, INC. (TMCI) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 27, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on April 9, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for TREACE MEDICAL CONCEPTS, INC. (TMCI) (SEC CIK 1630627), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Development, marketing, and sales of bunion correction surgical systems and instruments in the U.S., primarily via direct sales force and distributors
- • New products emphasized: Minimally invasive osteotomy systems (Nanoplasty, Percuplasty), great toe fusion system, and next-gen Lapiplasty Lightning Instrumentation expected in 2026
Management Discussion & Analysis
- • Revenue $212.7M in 2025, up 1.6% YoY from $209.4M in 2024
- • Net loss increased to $59.0M in 2025 from $55.7M in 2024; operating margin negative approx. -25.5% in 2025 vs -26.6% in 2024 (loss from operations $54.2M vs $55.7M)
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • Newly added litigation risk triggered by October 2024 and May/August 2025 lawsuits against Stryker and Zimmer Biomet for patent infringement seeking damages and injunctive relief
- • Most materially updated financial risk: inclusion of $11.0 million initial stocking distributor sales in 9M 2025, expected not to recur, impacting revenue recognition
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Full-year 2025 financial results released Feb 27, 2026 — details in Exhibit 99.1
- • TMCI reports annual earnings; revenue trends and profitability metrics disclosed in accompanying press release
Annual Reports Archive10-K
AI-powered analysis of TREACE MEDICAL CONCEPTS, INC. (TMCI) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of TREACE MEDICAL CONCEPTS, INC. (TMCI) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of TREACE MEDICAL CONCEPTS, INC. (TMCI) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | — | $187.1M | $209.4M | $212.7M |
| Gross Profit | — | $151.9M | $168.3M | $169.8M |
| Operating Income | — | -$51.4M | -$55.7M | -$54.2M |
| Net Income | -$42.8M | -$49.5M | -$55.7M | -$59.0M |
| Gross Margin | — | 81.2% | 80.4% | 79.8% |
| Op. Margin | — | -27.5% | -26.6% | -25.5% |
| Net Margin | — | -26.5% | -26.6% | -27.7% |
| Balance Sheet | ||||
| Total Assets | $159.0M | $251.9M | $217.1M | $190.6M |
| Equity | — | $137.9M | $112.9M | $87.3M |
| ROE | — | -35.9% | -49.4% | -67.6% |
Source: XBRL financial data from TREACE MEDICAL CONCEPTS, INC. (TMCI) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 9, 2026 | — | — | — |
8-K | Feb 27, 2026 | — | Analysis | — |
10-K | Feb 27, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 13, 2026 | — | — | |
8-K | Dec 18, 2025 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 5, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Feb 27, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 9, 2023 | Mar 31, 2023 | — | |
10-K | Mar 8, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 9, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 10, 2022 | Jun 30, 2022 | — | |
10-Q | May 6, 2022 | Mar 31, 2022 | — | |
10-K | Mar 4, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 25, 2021 | Mar 31, 2021 | — |
Frequently Asked Questions
What are the latest TMCI SEC filings in 2026?
TREACE MEDICAL CONCEPTS, INC. (TMCI) has filed a 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on April 9, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did TMCI file its most recent 10-K annual report?
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed its most recent 10-K annual report on February 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view TMCI 10-Q quarterly reports?
TREACE MEDICAL CONCEPTS, INC. (TMCI)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every TMCI 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has TMCI filed recently?
TREACE MEDICAL CONCEPTS, INC. (TMCI)'s most recent 8-K was filed on April 9, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find TMCI insider trading activity (Form 4)?
SignalX aggregates every TMCI Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does TMCI file with the SEC?
TREACE MEDICAL CONCEPTS, INC. (TMCI) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TMCI filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for TREACE MEDICAL CONCEPTS, INC. (TMCI).
What is TMCI's SEC CIK number?
TREACE MEDICAL CONCEPTS, INC. (TMCI)'s SEC CIK (Central Index Key) number is 1630627. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1630627 to look up all TMCI filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find TMCI return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from TREACE MEDICAL CONCEPTS, INC. (TMCI) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of TREACE MEDICAL CONCEPTS, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 24+ filings.